Milton, MA, United States of America

Brad Jameson


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Brad Jameson

Introduction

Brad Jameson is an accomplished inventor based in Milton, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compositions that target specific interactions in the immune system. His work is characterized by a focus on innovative solutions to complex medical challenges.

Latest Patents

Jameson holds a patent for "Pharmaceutical compositions thereof, and methods of using same." This invention relates to peptidomimetics capable of inhibiting the interaction between CD28 and/or CTLA-4 with CD80 (B7-1) and CD86 (B7-2). The core amino acid sequence of his invention is LeuMetTyrProProProTyrTyr, which corresponds to residues 2 to 9 of SEQ ID NO:1. The patent also encompasses pharmaceutical compositions and methods for treating various pathologies and disorders that can be improved by inhibiting these interactions.

Career Highlights

Jameson is associated with Applied Research Systems Ars Holding N.V., where he continues to push the boundaries of pharmaceutical research. His innovative approach has led to advancements that could potentially improve treatment options for patients suffering from immune-related disorders.

Collaborations

Throughout his career, Jameson has collaborated with notable professionals in the field, including Nabil El Tayar and Steven Blechner. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking pharmaceutical solutions.

Conclusion

Brad Jameson's contributions to pharmaceutical innovations demonstrate his commitment to advancing medical science. His patent and collaborative efforts reflect a dedication to improving healthcare outcomes through innovative research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…